The Road to End-Stage Liver Disease: From Function Dysregulation to Architecture Remodeling
A special issue of Biomolecules (ISSN 2218-273X).
Deadline for manuscript submissions: closed (30 June 2022) | Viewed by 12751
Special Issue Editor
Interests: End-stage liver disease; liver regeneration; signaling and transcriptional regulation
Special Issue Information
Dear Colleagues,
Although there are a large number of initiating factors, the end results of liver diseases are few. Acute or chronic liver failure and portal hypertension are the two main pathophysiological alterations and clinical syndrome corresponding to the end-stage liver disease. From initiating damage to end-stage liver disease, the liver undergoes a series of functional and architectural changes, including parenchymal cell death, dysregulated immune response, failed wound healing (fibrosis), insufficient regeneration, and a distorted vascular system. Intercross different disease initiating factors lead to these severe outcomes through different mechanisms, which are relevant to different live cells, inflammatory factors, and signaling. Clarification of these mechanisms is essential and critical to understand how a healthy liver goes to disease end point.
This Special Issue entitled “The Road to End-Stage Liver Disease: From Function Dysregulation to Architecture Remodeling” provides a platform that highlights the current understanding of several crucial aspects contributing to the progress from liver damage to end-stage liver disease. The topic collection also focuses on the controversial issues relevant to wound healing, vascular remodeling, liver regeneration, and liver failure.
Dr. Honglei Weng
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- End-stage liver disease
- Liver failure
- Liver regeneration
- Portal hypertension
- Vascular remodeling
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
